Pfizer Inc. (PFE) News

Pfizer Inc. (PFE): $33.85

0.09 (-0.27%)

POWR Rating

Component Grades








Filter PFE News Items

PFE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PFE News Highlights

  • PFE's 30 day story count now stands at 26.
  • Over the past 25 days, the trend for PFE's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
  • The most mentioned tickers in articles about PFE are DRUG, AMP and TALK.

Latest PFE News From Around the Web

Below are the latest news stories about PFIZER INC that investors may wish to consider to help them evaluate PFE as an investment opportunity.

3 Stocks to Buy in October That Could Soar More Than 40% Over the Next 12 Months, According to Wall Street

BioNTech (NASDAQ: BNTX) has turned in a dismal performance so far this year. The average analysts' price target reflects an upside potential of 56%. Granted, not every analyst is all that bullish about BioNTech.

Yahoo | October 1, 2023

Could Viatris Stock Help You Become a Millionaire?

Viatris' broad portfolio gives the business lots of stability and plenty of opportunities -- but is there enough there for the stock to be a great long-term investment?

Yahoo | September 30, 2023

Moderna's Shares Could Take Off if These 2 Things Happen

Moderna (NASDAQ: MRNA) used to be a stock market star, climbing 1,700% from the start of 2020 through July of 2021. Investors liked that, and it clearly showed in the stock performance. After all, the vaccine is Moderna's only product right now, and demand for it has declined.

Yahoo | September 30, 2023

Unveiling Pfizer (PFE)'s Value: Is It Really Priced Right? A Comprehensive Guide

A deep dive into Pfizer's current market valuation, financial strength, and growth prospects

Yahoo | September 29, 2023

Why Pfizer and BioNTech Stocks Zoomed Higher Today

The fight against COVID-19 isn't over yet, and the two companies remain very much in the battle.

Yahoo | September 29, 2023

Structure Stock Soars. Its Obesity Pill Could Challenge Lilly, Novo.

Analysts say that the arrival of cheaper, more convenient obesity pills could mean much broader access for patients, and eventually a larger market.

Yahoo | September 29, 2023

Upstart Weight-Loss Drugmaker Jumps 75% on Strong Test Results

(Bloomberg) -- Structure Therapeutics Inc. jumped to a record high Friday after new data on its oral weight-loss drug fueled expectations that the San Francisco-based company is closing the gap with larger competitors such as Pfizer Inc.Most Read from BloombergEurope’s Richest Royal Family Builds $300 Billion Finance EmpirePakistan Rupee Set to Become Top Performing Currency Globally Top Chinese Scientist Claims India Moon Landing Nowhere Near South PoleStock Optimism Fizzles as Quarterly Losses

Yahoo | September 29, 2023

3 Stocks to Focus on as Demand for Obesity Drugs Booms

With the obesity market gaining popularity, analysts are expecting sales to increase. Pharma companies are rushing to enter the market

Yahoo | September 29, 2023

Where Will Pfizer Be in 5 Years?

Investors should expect to see big changes from the company as it addresses concerns about its growth prospects.

Yahoo | September 29, 2023

Bud Light boycott movement goes after Taylor Swift and Travis Kelce

The Kansas City Chiefs tight end has become a popular spokesperson who has endorsed both Bud Light and Pfizer.

Yahoo | September 29, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!